Abstract 41P
Background
Triple-negative breast cancer (TNBC) is associated with more aggressive disease and worse survival compared to other breast cancer subtypes. We aim to analyze the role of oncogenic mir-223 as a possible negative driving factor in TNBC through its prognostic value and association with unfavorable clinicopathologic characteristic.
Methods
We retrospectively analyzed the association of pre-treatment mir-223 expression with clinicopathologic characteristics and 3-years overall survival (OS) of Indonesian TNBC patients treated in a tertiary center during 2014-2017. Cytokeratin5/6 (CK5/6) and Epidermal Growth Factor Receptor (EGFR) expressions were examined using immunohistochemistry by 2 independent blinded pathologists. Mir-223 level of tumor tissue was measured using Real-Time qRT-PCR. Cutoff value for mir-223 was determined using Receiver Operating Curve (ROC). Chi-square and Fisher’s exact tests were used to analyze the association between categorical variables, while Kaplan-Meier curve was used to perform survival analysis.
Results
Fifty-three stage I-IV TNBC patients were included in the analysis. The mean age of our patients was 51.3 years old. Early stage, locally advanced stage, and metastatic disease respectively were found in 7 (13.2%), 38 (71.7%), and 8 (15.1%) patients. The optimal cutoff value for mir-223 was 23.435 (AUC: 0.706, 95%CI: 0.565-0.848; p: 0.01; Sensitivity: 78.6%; Specificity: 56%) and was used to classify mir-223 expression into over- and under-expressed groups. Mir-223 overexpression was associated with increased expression of EGFR (69.7% vs. 35%, p: 0.022) and lower 3-years OS (33.3% vs. 70%; mean OS±SE (months): 25.66±1.58 vs. 30.23±1.99; p log rank: 0.029). No significant association was observed between mir-223 expression with other clinicopathologic characteristics (age, BMI, stage, tumor size, nodal status, distant metastasis, and CK5/6 expression).
Conclusions
Pre-treatment mir-223 level of expression in Indonesian TNBC patients is correlated with poor survival through increase of EGFR expression. Thus, targeting mir-223 becomes a potential therapeutic strategy for TNBC patients. However, further study is needed to validate this result.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
403P - Clinical profile, practice pattern and outcomes in ALK-positive lung cancer: Real-world data from India
Presenter: Akhil Kapoor
Session: e-Poster Display Session
404P - Financial toxicity in patients with advanced lung cancer treated with immunotherapy: Has it an effect on the clinical decision?
Presenter: Jia-Hui Weng
Session: e-Poster Display Session
405P - Promising efficacy as combination therapy of DFP-14323, protease inhibitor, with EGFR-TKI in patients with metastatic NSCLC harboring EGFR mutation
Presenter: Hiroshige Yoshioka
Session: e-Poster Display Session
406P - Anti-PD-1 versus anti-PD-L1 inhibitors in first-line therapy non-small-cell lung cancer: A systematic review and meta-analysis
Presenter: Angelo Brito
Session: e-Poster Display Session
407P - Integrating histologic and genomic characteristics to predict tumour mutation burden of early-stage non-small cell lung cancer
Presenter: Yuan Qiu
Session: e-Poster Display Session
408P - Integrated chemotherapy with EGFR receptor tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring EGFR mutation
Presenter: Julia Maevskaya
Session: e-Poster Display Session
409P - Effect of transdermal granisetron on prevention of nausea and vomiting during chemotherapy of lung cancer
Presenter: Haifeng Qin
Session: e-Poster Display Session
410P - Frequency and spectrum of primary resistance mechanism in Chinese ALK+ non-small cell lung cancer patients progressing on crizotinib: A multicenter study
Presenter: Wen-xian Wang
Session: e-Poster Display Session
411P - Impact of pre-treatment AXL expression on osimertinib efficacy in patients with non-small cell lung cancer with EGFR mutation
Presenter: Yoshihiko Taniguchi
Session: e-Poster Display Session
412P - Treatment patterns and selection criteria for advanced non-small cell lung cancer (NSCLC) patients unfit for platinum-based first-line therapy: Results of the MOON-OSS observational trial
Presenter: Andrea Camerini
Session: e-Poster Display Session